GE HealthCare (GEHC) announced that Cardiovascular Associates of America, or CVAUSA, the largest network of private cardiology groups in the U.S., plans to broaden its adoption of GE HealthCare’s FDA-approved cardiac positron emission tomography radiotracer Flyrcado injection, across approximately 25 sites following a successful pilot at Cardiovascular Medicine in Davenport, Iowa. This planned rollout marks a significant milestone for advancing PET myocardial perfusion imaging in community cardiology settings and reflects growing confidence in Flyrcado’s role in shaping the future of cardiac imaging.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GEHC:
- Hold Rating Justified for GE Healthcare Technologies Amid Limited Impact from Generic Omnipaque Launch
- GE HealthCare, RadNet to expand AI collaboration
- GE HealthCare management to meet with Piper Sandler
- GE Healthcare’s Earnings Call: Growth Amid Challenges
- GE HealthCare price target lowered to $87 from $89 at Wells Fargo